On June 5, 2026, the Company implemented an organizational realignment designed to align its commercial operations into two global reportable segments by combining the previously reported Plasma and Blood Center reportable segments into Apheresis and renaming the Hospital reportable segment to MedSurg. This organizational structure reflects how the Company is organized to manage operations, allocate resources and evaluate performance.

The Company has recast goodwill assigned to the Apheresis segment as of the beginning of the year by combining the goodwill from the previous Blood Center and Plasma segments into the new Apheresis segment. Each of the Company’s reporting units were tested for goodwill impairment prior to and subsequent to the re-alignments and no impairment was identified.


	Apheresis		MedSurg		Total

	(Dollars in Thousands)
Carrying amount as of March 28, 2026	$	55,931	$	600,437	$	656,368

Purchase accounting adjustments	—		1,714		1,714

Currency translation	(22)		(1,176)		(1,198)
Carrying amount as of June 27, 2026	$	55,909	$	600,975	$	656,884

The gross carrying amount of intangible assets and the related accumulated amortization as of June 27, 2026 and March 28, 2026 are as follows:


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)


June 27, 2026	(Dollars in Thousands)
Amortizable:
Developed technology	$	554,029	$	201,421	$	352,608	11.4
Customer contracts and related relationships	129,601		77,475		52,126		11.1
Capitalized software	97,636		83,741		13,895		3.1
Patents and other	7,422		4,763		2,659		5.3
Trade names	14,608		7,428		7,180		10.2
Total	$	803,296	$	374,828	$	428,468

Non-amortizable:
In-process software development	$	6,044


Total	$	6,044


	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted Average Remaining Life (Years)

March 28, 2026	(Dollars in Thousands)
Amortizable:
Developed technology	$	556,631	$	193,114	$	363,517	11.6
Customer contracts and related relationships	130,862		76,489		54,373		11.3
Capitalized software	95,880		82,284		13,596		2.9
Patents and other	7,422		4,613		2,809		5.5
Trade names	14,720		7,263		7,457		10.4
Total	$	805,515	$	363,763	$	441,752

Non-amortizable:


In-process software development	$	5,903
Total	$	5,903

During fiscal 2026, the Company recorded total intangible asset impairment charges of $86.5 million. This included a $9.3 million intangible impairment charge related to the intellectual property associated with the HAS viscoelastic diagnostic devices, related assays and disposables within the MedSurg reportable segment, which was primarily recorded in the second quarter of fiscal 2026, and an intangible asset impairment charge of $77.2 million related to long-lived intangible assets associated with the acquisition of Attune Medical within the MedSurg reportable segment in the fourth quarter of fiscal 2026.

In the fourth quarter of fiscal 2026, the Company acquired Vivasure and recorded $117.1 million of developed technology based on the purchase accounting valuation. Refer to Note 3, Acquisitions and Strategic Investments, for additional information regarding the acquisition.

Intangible assets include the value assigned to license rights and other developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

During the three months ended June 27, 2026 and June 28, 2025, amortization expense was $11.8 million and $13.3 million, respectively.


	Amortization Expense
	(Dollars in Thousands)
Remainder of Fiscal 2027	$	34,659
Fiscal 2028	$	44,832
Fiscal 2029	$	43,585
Fiscal 2030	$	42,317
Fiscal 2031	$	40,690